浙江仙琚制药股份有限公司 董事会关于独立董事独立性自查情况的专项报告 根据《上市公司独立董事管理办法》《深圳证券交易所股票上市规则》《深 圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》及《公司 章程》等相关规定，结合独立董事出具的《独立董事独立性情况自查表》，浙江仙 琚制药股份有限公司（以下简称"公司"）董事会就公司在任独立董事张红英女 士、郝云宏先生、刘斌先生的独立性情况进行评估并出具如下专项意见： 经核查独立董事张红英女士、郝云宏先生、刘斌先生的任职经历以及签署的 相关自查文件等内容，公司董事会认为上述人员未在公司担任独立董事以外的任何 职务，也未在公司主要股东担任任何职务，与公司以及主要股东之间不存在利害关 系或其他可能妨碍其进行独立客观判断的关系，不存在其他影响独立董事独立性的情 况，因此，公司独立董事符合《上市公司独立董事管理办法》《深圳证券交易所上 市公司自律监管指引第 1 号——主板上市公司规范运作》等相关法律法规及《公司 章程》中关于独立董事独立性的相关要求。 浙江仙琚制药股份有限公司 董事会 2025 年 4月 24 日 ...

浙江仙琚制药股份有限公司 市值管理制度 第一章 总则 第一条 为加强浙江仙琚制药股份有限公司（以下简称"公司"）市值管理工 作，进一步规范市值管理行为，增强投资者回报，维护投资者利益，依据《中华人民 共和国公司法》《中华人民共和国证券法》、中国证券监督管理委员会《上市公司监管 指引第 10 号——市值管理》《深圳证券交易所股票上市规则》《上市公司信息披露管理 办法》等其他有关法律法规规定，结合公司实际情况，制订本制度。 第二条 本制度所指市值管理，是指公司以提高公司质量为基础，为提升投资者 回报能力和水平而实施的战略管理行为。 公司应当牢固树立回报股东意识，采取措施保护投资者尤其是中小投资者利益， 创新引领、诚信经营、规范运作，积极推进公司高质量发展与股东回报双提升，积极 做好投资者关系管理，增强公司信息披露质量和公司透明度，必要时积极采取措施提 振投资者信心，推动公司股票价值合理反映公司内在价值。 公司高质量发展是公司投资价值的根本和市值管理的基础。公司应当立足提升公 司发展质量，依法依规运用各类方式提升公司投资价值。 第二章 市值管理的目的与基本原则 第三条 市值管理主要目的是通过充分合规的信息披露，增强 ...

浙江仙琚制药股份有限公司 独立董事2024年度述职报告 本人（刘斌）作为浙江仙琚制药股份有限公司(以下简称"公司")第八届董 事会的独立董事，在 2024 年度严格按照相关法律法规的规定和要求，勤勉、忠 实、尽责地履行独立董事职责，维护公司整体利益和全体股东尤其是中小股东的 合法权益，现就 2024 年度履职情况述职如下： 一、出席董事会及股东大会情况 1、出席董事会会议情况 2024 年度，公司召开董事会 6 次，本人均亲自参加，无缺席情况。 对于上述会议，本人在会议召开前根据公司会议通知上所列的审议事项，主 动搜集获取对作出决议所需的资料和信息，在董事会上认真审议每个议案并积极 参与讨论，本着勤勉、尽责和诚信、负责的原则，对董事会所有议案进行了认真 思考后投了赞成票，没有投反对票和弃权票的情况。 2、出席股东大会情况 2024 年度，公司共召开了 2 次股东大会（即 2023 年度股东大会和 2024 年第 一次临时股东大会），本人亲自参加了 2024 年第一次临时股东大会。 经核查，公司 2023 年度日常关联交易实际总发生情况整体未超出 2023 年度 的预计总范围，实际发生金额与原预计金额存在一定差 ...

前十大流通股东累计持有： 30292.14万股，累计占流通股比： 30.77%，较上期变化： -2074.36万股。 | 名称 | 持有数量(万股) | 占总股本 | 增减情 | | --- | --- | --- | --- | | | | 比例(%) | 况(万股) | | 仙居县产业投资发展集团有限公司 | 21322.18 | 21.66 | 不变 | | 中国人寿（601628）保险股份有限公司-传统-普通保险产 | | | | | 品-005L-CT001沪 | 1526.49 | 1.55 | -276.06 | | 国泰佳泰股票专项型养老金产品-招商银行股份有限公司 | 1516.30 | 1.54 | 75.97 | | 李勤俭 | 1152.00 | 1.17 | -216.38 | | 鹏华基金-中国人寿保险股份有限公司-分红险-鹏华基金国寿股 份成长股票型组合单一资产管理计划(可供出售) | 916.44 | 0.93 | 不变 | | 香港中央结算有限公司 | 871.74 | 0.89 | -177.12 | | 泰康人寿保险有限责任公司-传统-普通保险产品-019L-CT001深 ...

Financial Performance - The company's operating revenue for 2024 was ¥4,000,693,148.05, a decrease of 2.98% compared to ¥4,123,418,584.19 in 2023[6]. - The net profit attributable to shareholders for 2024 was ¥397,178,995.31, down 29.46% from ¥563,083,493.15 in 2023[6]. - The cash flow from operating activities for 2024 was ¥398,655,375.39, representing a decline of 33.05% compared to ¥595,482,358.68 in 2023[6]. - The basic earnings per share for 2024 was ¥0.40, a decrease of 29.82% from ¥0.57 in 2023[6]. - The total assets at the end of 2024 were ¥6,999,589,209.69, a slight increase of 0.10% from ¥6,992,835,052.50 at the end of 2023[6]. - The company achieved a total revenue of 4,000.69 million yuan in 2024, a year-on-year decrease of 2.98%[56]. - The operating profit was 678.21 million yuan, reflecting a year-on-year increase of 4.91%[56]. - The net profit attributable to shareholders decreased by 29.46% to 397.18 million yuan[56]. - The sales revenue from formulations reached 2,415 million yuan, an increase of 6.02% year-on-year, with self-operated product sales at 2,276 million yuan, up 8%[57]. - The sales revenue from raw materials and intermediates was 1,547 million yuan, a decline of 13.4% year-on-year[57]. Dividend Distribution - The company plans to distribute a cash dividend of 3 CNY per 10 shares to all shareholders, based on a total of 989,204,866 shares[5]. - The total cash dividend distributed amounts to CNY 296,761,459.80, representing 100% of the profit distribution[184]. - The remaining undistributed profits will be carried forward to the next fiscal year, with no stock dividends or capital reserve transfers planned for 2024[184]. Risks and Challenges - The company has identified several major risks, including industry policy changes, drug price reduction risks, quality control risks, and R&D risks[5]. - The company experienced a slight decline in revenue in 2024, primarily due to the impact of national and regional centralized procurement on the sales of certain formulation products like dexamethasone sodium phosphate injection[42]. - The company recognizes risks from regulatory changes, quality control, R&D challenges, and market dynamics, and will adapt its strategies accordingly[118]. - The company faces market risks such as raw material price fluctuations and intensified competition in generic drugs, which may lead to increased production costs and market share loss[120]. Research and Development - The company has a comprehensive R&D system with a focus on respiratory, gynecological, and dermatological fields, ensuring a robust product pipeline[48]. - The company is actively pursuing new drug applications, including several projects in the respiratory and gynecological fields[85]. - R&D investment increased to ¥265,172,350.80 in 2024, a 1.60% rise from ¥260,996,011.23 in 2023, with R&D expenses accounting for 6.63% of revenue, up from 6.33%[86]. - The company is focusing on enhancing its management capabilities and core competitiveness to navigate the challenges posed by a weak overall market demand and intense competition in the raw material drug sector[42]. Market and Sales Strategy - The company is focusing on innovation-driven strategies and industry upgrades to adapt to the evolving pharmaceutical landscape[30]. - The company is actively developing a systematic and digital sales capability for its formulation products, leveraging a multi-category product group advantage[43]. - The sales strategy will focus on market responsiveness, optimizing resource allocation, and enhancing new product coverage and sales volume[114]. - The company plans to enhance its global product opportunity map and deepen internal management to improve market insight and business development capabilities[116]. Governance and Management - The company has established a clear and independent governance structure, complying with relevant laws and regulations[139]. - The board of directors consists of 9 members, including 3 independent directors, ensuring compliance with governance requirements[135]. - The company has implemented a performance evaluation and incentive mechanism for senior management, based on annual financial and operational targets[137]. - The management team consists of experienced individuals, with several members having tenures extending to 2025[150]. Environmental Compliance - The company adheres to multiple environmental protection laws, including the Environmental Protection Law and the Air Pollution Prevention and Control Law, which have been in effect since 2015 and 2018 respectively[1]. - The company has received environmental approval for projects, including a hormone raw material production project with an annual capacity of 98 tons approved in 2021 and a production line for 30 million transdermal patches approved in June 2023[2][3]. - The company reported a total discharge of 38.84 tons of COD from its wastewater treatment, with a concentration of 149.23 mg/L, complying with local standards[5]. - The company has implemented measures to ensure that all emissions are within the regulatory standards, with no reported violations[200]. Future Outlook - The company anticipates that innovation and high-quality development will become the dual engines driving the future of the pharmaceutical industry[109]. - The 2025 operational plan emphasizes accelerating the development of complex generic products and innovative drugs to meet clinical needs, particularly in the steroid hormone treatment area[113]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 500 million CNY allocated for potential deals[125]. - The company plans to expand its production capacity to meet increasing market demand for its pharmaceutical products[200].

Financial Performance - The company's revenue for Q1 2025 was ¥1,008,198,242.30, a decrease of 2.86% compared to ¥1,037,926,735.62 in the same period last year[5] - Net profit attributable to shareholders was ¥143,983,992.29, down 4.72% from ¥151,121,862.92 year-on-year[5] - Basic earnings per share were ¥0.1456, reflecting a decline of 4.71% from ¥0.1528 in the same period last year[5] - Net profit for the current period is ¥138,163,788.77, a decline of 11.7% compared to ¥156,516,313.26 in the previous period[21] - Other comprehensive income after tax for the current period is ¥46,221,040.19, compared to a loss of ¥30,172,868.95 in the previous period[22] - The total comprehensive income for the current period is ¥184,384,828.96, an increase from ¥126,343,444.31 in the previous period[22] Cash Flow - The net cash flow from operating activities decreased by 83.10%, amounting to ¥18,421,732.02, compared to ¥109,025,001.56 in the previous year[5] - Cash inflow from operating activities totaled ¥809,426,287.89, slightly down from ¥825,567,894.71 in the previous period[23] - The net cash flow from operating activities was 18,421,732.02, a decrease from 109,025,001.56 in the previous period[24] - The net cash flow from investing activities was -69,733,941.91, compared to -63,759,854.47 previously, indicating increased investment outflows[24] - The net cash flow from financing activities was 5,132,399.86, a significant improvement from -15,199,172.59 in the prior period[24] - The cash outflow from operating activities totaled 791,004,555.87, compared to 716,542,893.15 previously, reflecting higher operational expenses[24] - The cash inflow from financing activities was 10,206,279.63, up from 500,000.00, indicating increased capital raising efforts[24] - The company paid 79,196,674.94 in taxes, an increase from 63,414,473.05, reflecting higher tax obligations[24] - The cash outflow for investing in fixed assets was 69,740,347.25, compared to 39,871,581.52, showing increased capital expenditures[24] Assets and Liabilities - Total assets increased by 1.84% to ¥7,128,642,277.18 from ¥6,999,589,209.69 at the end of the previous year[5] - Current assets totaled CNY 3,327,667,195.76, compared to CNY 3,263,717,834.91 at the start of the period, indicating a growth in liquidity[17] - The company's cash and cash equivalents decreased slightly to CNY 1,363,055,340.05 from CNY 1,381,890,699.25[16] - Total liabilities decreased to CNY 716,880,084.65 from CNY 778,089,858.12, indicating improved financial health[17] - The total liabilities amount to ¥1,055,185,380.16, a decrease from ¥1,111,417,141.63 in the previous period[18] - Long-term borrowings increased to ¥22,686,715.44 from ¥20,400,448.86 in the previous period[18] Shareholder Equity - The company's equity attributable to shareholders rose by 3.25% to ¥6,033,708,337.97 from ¥5,843,503,305.49 at the end of last year[5] - Total equity attributable to shareholders of the parent company increased to ¥6,033,708,337.97 from ¥5,843,503,305.49 in the previous period[18] Operational Metrics - The company reported a significant decrease in net cash flow from operating activities, primarily due to reduced cash receipts from sales and increased cash payments related to operating activities[9] - Short-term borrowings increased by 63.19%, amounting to an increase of ¥5,377,500 compared to the beginning of the year[12] - The company experienced a 341.78% increase in other comprehensive income, rising by ¥46,221,000, mainly due to foreign currency translation differences[12] - Financial expenses increased by 53.16%, amounting to an increase of ¥3,113,100, primarily due to reduced interest income[12] - Accounts receivable increased to CNY 668,550,016.07 from CNY 561,934,184.47, reflecting improved sales performance[16] - Inventory levels remained stable, with a slight decrease to CNY 922,328,200.69 from CNY 930,856,320.79[16] - The company's goodwill increased to CNY 602,096,680.76 from CNY 581,206,099.17, indicating potential acquisitions or investments[17] - The company reported a total of CNY 185,539,442.57 in other payables, slightly up from CNY 182,736,655.29, reflecting stable operational liabilities[17] - The company has not reported any significant changes in its major shareholders or their holdings during the period[14]

截至2025年4月10日收盘，仙琚制药(002332)报收于9.22元，上涨1.1%，换手率2.26%，成交量22.28万 手，成交额2.06亿元。 董秘最新回复 投资者： 请问贵司是不是国企？市值管理有没有落实？何时才能增持回购 董秘： 您好！感谢您对公司的关注。公司专注做好主业，持续提升运营效率和管理水平，促进公司长 期稳健可持续发展，努力为股东创造长期投资价值。谢谢！ 投资者： 贵司作为浙江地方国企理应积极响应浙江省国资委的号召，增持回购提振市场信心当好压舱 石。更何况贵司作为第一大股东，持股仅只有21%和其他国资相比相距甚远，希望贵司管理层能提高思 想觉悟。 董秘： 您好！感谢您对公司的关注。 投资者： 请问公司是不是被恶意做空？还是公司经营管理出现问题？整个市场只跟跌不跟涨。对于当 下这种情况，公司又该如何提振投资者信心？ 董秘： 您好！感谢您对公司的关注。 投资者： 请问董秘，2024年公司出口原料药及成品药中，出口美国占收入比例多少？ 董秘： 您好！公司原料药产品出口目前主要以欧盟、东南亚市场为主，出口美国市场的业务收入占比 较低。谢谢！ 投资者： 公司是不是暴雷了啊，天天跌，这种跌法正常吗？是 ...

Group 1 - The company has received approval from the National Medical Products Administration for the registration of Deoxymethyltestosterone tablets, which will enhance its gynecological product line and improve market competitiveness [1][3] - The approved product has the same specifications as the original product, containing 0.15 mg of Deoxymethyltestosterone and 20 mcg of Ethinyl Estradiol [2] - The reference formulation for the approved product is Mercilon^[®], which was developed by N.V. Organon and has been marketed in several countries since its launch in 1987 [1][2] Group 2 - The approval of Deoxymethyltestosterone tablets aligns with the company's strategy to expand its product offerings in the gynecological sector [3] - The product is indicated for contraception, which may address a significant market need [1] - The company acknowledges that drug development, production, and sales are subject to uncertainties influenced by national policies and market conditions [3]

证券代码：002332 证券简称：仙琚制药 公告编号：2025-007 浙江仙琚制药股份有限公司 去氧孕烯炔雌醇片，规格为每片含去氧孕烯 0.15 毫克和炔雌醇 20 微克， 参比制剂为欧盟上市的去氧孕烯炔雌醇片，商品名 Mercilon®。去氧孕烯炔雌醇 片该参比制剂由荷兰 N.V.Organon 公司开发，于 1987 年 10 月在荷兰上市；2007 年，Mercilon®在中国获批进口。去氧孕烯炔雌醇片的适应症为避孕。N.V.Organon 浙江仙琚制药股份有限公司（以下简称"公司"）于近日收到国家药品监督 管理局核准签发的关于去氧孕烯炔雌醇片的《药品注册证书》（证书编号： 2025S00652），公司去氧孕烯炔雌醇片被批准注册。现将相关情况公告如下： 申请内容：境内生产药品注册上市许可。 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。 二、药品的其他相关情况 关于取得去氧孕烯炔雌醇片境内生产药品注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 1 药品名称 剂型 ...

Investment Rating - The report initiates coverage with a "Buy" rating for the company [6]. Core Views - The company is a leading player in the steroid hormone industry, with a robust growth trend expected to resume in 2024 after overcoming collection risks [1][2]. - The company has demonstrated consistent profit growth over 35 consecutive quarters, indicating strong business resilience [1]. - The report forecasts a compound annual growth rate (CAGR) of 10.6% for the company's formulation business from 2024 to 2026, driven by the clearance of collection risks and the launch of specialty products [2][3]. Summary by Sections 1. Collection Risk Clearance and Performance Recovery - The company has effectively navigated the challenges posed by collection policies, with a significant recovery in performance anticipated starting in 2024 [1][14]. - The formulation business has faced temporary setbacks due to high baseline products affected by collection policies, but these impacts are expected to diminish [1][14]. 2. Formulation Business - The impact of collection policies on high baseline products has largely been resolved, paving the way for growth in low baseline products [2][25]. - The company has several complex and hard-to-generate products that are expected to contribute significantly to revenue growth in the short to medium term [3][25]. - The report anticipates a 10.6% revenue growth for the formulation business from 2024 to 2026, supported by the introduction of new products and the recovery of existing ones [2][25]. 3. Active Pharmaceutical Ingredients (APIs) - The company’s API business is expected to stabilize as the inventory destocking cycle among downstream customers comes to an end [3][25]. - The company is focusing on upgrading its product offerings and increasing its share in high-end markets, with a projected CAGR of 6.2% for the API business from 2024 to 2026 [3][25]. 4. Financial Forecast and Investment Recommendations - The company is projected to achieve net profits of 633 million, 727 million, and 847 million yuan for the years 2024, 2025, and 2026, respectively, reflecting year-on-year growth rates of 12.4%, 14.9%, and 16.5% [5][3]. - The report suggests that 2024 will mark a turning point for the company, allowing it to return to a stable growth trajectory [3][5].